Evidence map›Paper›PMID 40377673›Full record

Observational studyAnnals of hematology2025

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.

Yuhong Ren, Hui Tan, Jingli Zhuang, Luya Cheng, Ling Yuan, Lili Ji, Yang Ke, Xuejiao Zhang, Zhixiang Cheng, Jing Li and 1 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06203652 (The Pathogenesis and Prognostic Factors of Lymphoma), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06203652 recruitingnot on this map

The Pathogenesis and Prognostic Factors of Lymphoma

Typeobservational_patient_registrySponsorShanghai Zhongshan HospitalRan2023 to 2028Enrolled2,000ConditionsLymphoma, Hodgkin Lymphoma, Non-hodgkin LymphomaArmsReal-world regimen
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuhong Ren *Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.ORCID http://orcid.org/0000-0003-0330-4125
Hui Tan *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingli Zhuang *Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Luya ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Ling YuanDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Lili JiDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Yang KeDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Xuejiao ZhangDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Zhixiang ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Jing LiDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China. liu.peng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9639-6606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First-line treatment balancing efficacy and safety is urgently needed for frail and elderly diffuse large B-cell lymphoma (DLBCL) patients. We designed a triplet chemo-light regimen, Pola-ZR, in previously untreated frail and elderly DLBCL patients to assess the efficacy and safety in a prospective DLBCL cohort (NCT06203652). Polatuzumab vedotin was given 1.8 mg/KG intravenously on day 1, zanubrutinib 160 mg twice a day orally from day 1 to day 21, and rituximab 375 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesLymphoma, Large B-Cell, DiffusePyrazolesPyrimidinesRituximabAgedAged, 80 and overAntibodies, MonoclonalFemaleFrail ElderlyHumansMaleMiddle AgedOxazinesPiperidinesAntibodies, MonoclonalImmunoconjugatesOxazinesPiperidinespolatuzumab vedotinPyrazolesPyrimidinesRituximabzanubrutinibDiffuse large B-cell lymphomaElderlyPolatuzumab vedotinResponseZanubrutinib

Identifiers

PMID40377673
PMCPMC12141111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.